CSI Market
Sign In | Register

Biodesix Inc (BDSX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access BDSX Annual Cash Flow →
Reviewing cash flow figures over time highlights how Biodesix Inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-15.07
Depreciation & amortization4.58
Amortization of Other Assets1.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Intangible Assets, Finite-lived0.02
Provision For Loan Losses Expensed0.12
Inventory Write-down0.03
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation1.94
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Accrued Interest On Notes Payable And Convertible Notes Payable-
Operating Lease Right Of Use Asset Amortization Expense-
Increase Decrease In Contract With Customer Liability-0.77
Accretion Reduction Of Lease Right Of Use Assets-
Operating Lease Right Of Use Asset Reduction Accretion Amortization Expense0.02
Accrued Interest Amortization Of Debt Issuance Costs And Other0.33
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.19
Increase (Decrease) in Accounts Payable and Accrued Liabilities-1.58
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital-1.05
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.91
Discontinued operations0.00
Net Cash flow from Operating Activities-11.73
Investing Activities
Capital Expenditures-0.28
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net-0.06
Payments To Acquire Oncimmune-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-0.12
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.40
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.04
Long-term debt - borrowings0.00
Long-term debt - repayments-0.01
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock23.90
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-0.31
Other net-0.40
Proceeds From Issuance Of Term Loan And Notes Payable-
Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan0.35
Payment Of Equity Financing Costs-0.48
Payment Of Deferred Offering Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities23.14
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-12.01
Total Cash Flow11.01
4 historic quarters locked

Sign in to unlock the full Biodesix Inc cash flow history.

Sign In Create Free Account

About Biodesix Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-335036

Figures are derived from filed reports and may be restated. Historical data is subject to revision.